ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma.
Katrina S PedersenNathan R FosterMichael James OvermanPatrick M BolandSunnie S KimKathryn A ArrambideBrandy L JaszewskiTanios Bekaii-SaabRondell P GrahamJack WelchRichard H WilsonRobert R McWilliamsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In the largest study of SBA to date, pembrolizumab did not induce the hypothesized response rate; however, we did identify responses in key biomarker-selected cohorts.